Asiya Giniatullina, PhD
Asiya is Senior Associate in the Naarden office, and joined the Forbion team in 2018.
Between 2013 and 2018, Asiya has worked at bluebird bio in Cambridge MA in Business Development, Alliance Management and Research Strategy roles. At bluebird, Asiya has contributed to expanding the company pipeline by helping identify and evaluate early-stage technologies (e.g. gene editing, resulting in the acquisition of gene editing company Pregenen) and new disease indications. She has been involved in executing and managing several collaborative projects in gene therapy. Most recently, she has led the planning and execution of a program for a new gene therapy product candidate, from ideation through proof-of-concept study, and mapping out the development plan.
Before moving to the US and joining bluebird bio, Asiya worked as analyst intern at Forbion, participating in the deal-flow team.
Asiya holds a Ph.D. in Neuroscience from the VU University Amsterdam, M.S. in Medical Biotechnology and B.S. in Biotechnology from the University of Trieste, Italy.